Sacramento, CA , April 20, 2018 (GLOBE NEWSWIRE) — A new report and video has been published on Innovest Global, Inc. (OTC PINK: IVST). Innovest Global, Inc. is a diversified holding company that focuses on acquiring niche, high-growth businesses that are capable of generating significant annual revenue. The company’s planned subsidiaries operate across telehealth, biotech, commercial energy, business-to-business distribution, national call center and auto sales.
The report provides an overview of Innovest Global, Inc., its subsidiaries, financials, industry analysis and more. The content also covers the global outlook for the brain tumor and LED lighting markets.
Grand View Research: Brain Tumor Diagnostics and Therapeutics Market Forecast to Reach $773.10 Million By 2025
Innovest Global’s primary operating divisions are across commercial/industrial energy and biotech & health sciences. Both divisions have deep roots in high-growth markets with long term potential.
The brain tumor diagnostics and therapeutics market is estimated to be worth $773.10 million by 2025, according to Grand View Research. The market research firm sees the massive growth due to the “increasing incidence of various brain cancers, particularly glioblastoma.”
According to Renub Research, the global LED lighting market is estimated to be worth $100 billion by the end of 2024. The market research firm sees the vast global growth primarily stemming from exponential global urbanization and greater awareness to energy efficiency systems.
Health and energy are two key areas of the market that will consistently see demand and growth over the long-term. Civilizations require adequate health care and energy capabilities, which are also constantly being updated and innovated. The long-term suggests strength for the brain tumor treatment and LED lighting markets, which will be highly beneficial for Innovest Global.
Innovest Sees Q1 Revenue Beating Estimates, 50 Million Common Shares Cancelled
On April 16th, Innovest Global released their first quarter 2018 earnings report. The company reported total revenues greater than $708,000, gross profit of just under $330,000, and cash on hand greater than $600,000. Furthermore, the company reported total current assets of $932,096 and total current liabilities of $352,165, giving Innovest Global a strong quick ratio of 2.60, which is four times stronger than the conglomerate industry average of 0.60.
Management announced it has also cancelled 50 million common shares, which provides the company with the updated share structure, as of March 31st:
– Authorized Shares: 500 Million
– Outstanding Shares: 96.52 Million
– Shares in Float: 11.80 Million
“The response we are getting from business and technology owners that want to get to the next level is very encouraging,” said Innovest CEO, Dan Martin. “We are incrementally increasing the size of the organizations we are looking to acquire and seeing great progress.”
Entering into the second quarter, Innovest Global is now generating baseline quarterly revenues of around $800,000, just from its Commercial & Industrial Energy division alone. This comes as management is scheduled to officially launch its Biotech & Health Sciences division this Spring.
Innovest Global recently announced that it has signed a Letter of Intent to acquire a 20% stake in StemVax Therapeutics, a biotechnology company that is currently developing a brain cancer vaccine.
The StemVax Glioblast (SVX-GB) cancer vaccine is being designed and formulated to help restore a patient’s immune system in order to fight off existing cancer cells within the body. The vaccine is designed to fight against glioblastoma brain cancers, which is the same type of tumor that is currently affecting Arizona Senator John McCain.
Innovest Global, Inc. was also featured on an episode of Spotlight Growth Live, a video web series that focuses on emerging growth companies.
For more information on Innovest Global, Inc.,
SpotlightGrowth.com is a digital hub for micro-caps, small-caps, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small cap companies.
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/